Integrating the 31-gene expression profile and clinicopathologic data to determine the risk of sentinel lymph node positivity and recurrence-free survival in cutaneous melanoma

Main Article Content

Brian Martin
Castle Biosciences, Inc., Friendswood, TX

Nicholas Taylor
Zitelli and Broadland, P.C

Eric Whitman
Atlantic Heath System Cancer Care, Morristown, NJ

Ann Quick
Castle Biosciences, Inc., Friendswood, TX

Christine Bailey
Castle Biosciences, Inc., Friendswood, TX

Kyle Covington
Castle Biosciences, Inc., Friendswood, TX

John Vetto
Oregon Health & Science University, Portland, OR.

Keywords

GEP, SLNB, melanoma, recurrence free survival

Abstract

N/A

References

1. Gerami, P. et al. Clin Cancer Res 2015. 21 (1) 175-183

2. Keller, J. et al. Cancer Med 2019. 8 (5) 2205-2212.

3. Zager, J. et al. BMC Cancer 2018. 18 (1) 130.

4. Whitman, E. et al. JCO PO 2021. (5) 1466-1479.

5. Hsueh, E. et al. JCO PO 2021. 5 589-601.

6. Podlipnik, S. et al. JEADV 2019. 33 (5) 857-862.

7. Arnot, S. et al. AJS 2021.

8. Dillon, L. et al. SKIN 2018. 2 (2) 111–121.

9. Gastman, B. et al. JAAD 2019. 80 (1) 149-157.e4.

10. Gastman, B. et al. Head & Neck 2019. 41 (4) 871-879.

11. Chen, J. et al. Oncotarget 2016. 7 (29) 45671-45677.

12. Morton, D. et al. NEJM 2014. 370 (7) 599-609.

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.80

Article Details

How to Cite
Martin, B. ., Taylor, N., Whitman, E., Quick, A., Bailey, C., Covington, K. ., & Vetto, J. (2021). Integrating the 31-gene expression profile and clinicopathologic data to determine the risk of sentinel lymph node positivity and recurrence-free survival in cutaneous melanoma. SKIN The Journal of Cutaneous Medicine, 5(6), s80. https://doi.org/10.25251/skin.5.supp.80
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>